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Introduction: Many low- and middle-income countries are implementing strategies to increase dialysis
availability as growing numbers of people reach end-stage renal disease. Despite efforts to subsidize care,
the economic sustainability of chronic dialysis in these settings remains uncertain. We evaluated the as-
sociation of medical subsidy with household ﬁnancial hardship related to hemodialysis in Kerala, India, a
state with high penetrance of procedure-based subsidies for patients on dialysis.
Methods: Patients on maintenance hemodialysis at 15 facilities in Kerala were administered a question-
naire that ascertained demographics, dialysis details, and household ﬁnances. We estimated direct and
indirect costs of hemodialysis, and described the use of medical subsidy. We evaluated whether presence
of subsidy (private, charity, or government-sponsored) was associated with lower catastrophic health
expenditure (deﬁned as $40% of nonsubsistence expenditure spent on dialysis) or distress ﬁnancing.
Results: Of the 835 patients surveyed, 759 (91%) reported their households experienced catastrophic
health expenditure, and 644 (77%) engaged in distress ﬁnancing. Median dialysis-related expenditure was
80% (25th–75th percentile: 60%–90%) of household nonsubsistence expenditure. Government subsidies
were used by 238 (29%) of households, 139 (58%) of which were in the lowest income category. Cata-
strophic health expenditure was present in 215 (90%) of households receiving government subsidy and
332 (93%) without subsidy.
Conclusions: Provision of medical subsidy in Kerala, India was not associated with lower rates of
household ﬁnancial hardship related to long-term hemodialysis therapy. Transparent counseling on
impending costs and innovative strategies to mitigate household ﬁnancial distress are necessary for
persons with end-stage renal disease in resource-limited settings.
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D ialysis is among the most expensive of commonlyused life-sustaining medical treatments. As more
low- and middle-income countries work to improve
availability of dialysis,1,2 experts are calling for
thoughtful strategies for its use, with a focus on inten-
sive patient counseling regarding the medical and
ﬁnancial burdens of therapy.3
In India, the government has committed to more
extensive public ﬁnancing of health care.4 Nonetheless,
health care expenditures still remain punishingly high;
up to 37 million people are forced below the poverty
line in India each year due to out-of-pocket medical
costs.5,6 For dialysis, medical subsidy plans at the
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central and state levels offer reimbursement of the
dialysis procedure for persons with incomes below the
poverty level.7 However, the extent to which govern-
ment subsidy defrays the substantial costs of therapy
and protects households from impoverishment is un-
known. At the same time, demand is experiencing
unfettered growth: estimates of chronic kidney disease
prevalence in India range from 9% to 17%,8–10 and
poor risk factor control may cause substantial numbers
to reach end-stage renal disease (ESRD).9
We conducted a study to understand the household
ﬁnancial burden of hemodialysis in persons with ESRD
in Kerala, India. Kerala represents a best-case scenario
for persons on dialysis in India: it is the highest per-
forming state on measures of human development,11
and overall health indices, such as infant mortality
and life expectancy, are superior to most of India.12,13
The state government provides subsidies to public
and private hospitals for dialysis costs on a continuous
basis, and any person with ESRD is eligible for reduced
treatment (dialysis procedural) fees, irrespective of
ﬁnancial status.14,15 Among patients who are consid-
ered below the poverty line, national health insurance
coverage (called “RSBY,” or Rashtriya Swasthya Bima
Yojana) and charity-based supplementation of medical
expenses is common, with the latter being acquired
directly via individual lottery or indirectly via hospital
arrangements with nongovernmental organiza-
tions.7,16–18 Compared with coverage provided by
government initiatives, the private insurance market
remains small and is typically obtained via individual
purchase or employer sponsorship.19
From our survey at 15 dialysis units in North and
South Kerala, we report the proportion of patients on
hemodialysis who receive a medical subsidy, and
evaluate the association between medical subsidy and
household catastrophic health expenditure and distress
ﬁnancing. We also estimate and rank the direct and
indirect costs of hemodialysis therapy as experienced
on a household level.
METHODS
We presented study rationale and design at local Indian
Society of Nephrology meetings in Kerala’s capital city,
Thiruvananthapuram. We reached out to public (i.e.,
government-run) and private institutions and were
able to engage 2 public and 13 private facilities in
North and South Kerala (which according to available
published data represent 35% of all registered facilities
[n ¼ 40, 5 public and 35 private]).20
Study Population and Data Collection
We recruited persons$18 years of age with a diagnosis
of ESRD who had been on maintenance hemodialysis for
at least 1 month. At each dialysis facility, a lead research
assistant or site principal investigator conducted study
orientation and training on questionnaire administra-
tion for dialysis nurses or unit managers. Each unit was
also provided with a reference sheet that clariﬁed
frequently asked questions. Eligible patients were
approached consecutively and, in those who provided
informed consent, a structured questionnaire was
administered in either Malayalam, Tamil, or English.
The questionnaire ascertained patient demographics,
cause of ESRD, comorbidities, hospitalizations, dialysis
prescription, and availability and amount of medical
subsidy. Self-reported medical history was conﬁrmed
via medical chart review. In this same questionnaire, we
asked patients to estimate monthly direct (dialysis pro-
cedure, medications, clinic, and laboratory) and indirect
(travel, self-wage loss, relatives’ wage loss) out-of-
pocket costs related to hemodialysis (Supplementary
Table S1).
Measures of Household Financial Hardship
We deﬁned catastrophic health expenditure as monthly
out-of-pocket dialysis-related expenditure $40% of
monthly household nonsubsistence (or nonfood)
expenditure, as commonly used in the literature.21–25
The World Health Organization also uses the
following deﬁnitions of catastrophic health expendi-
ture: monthly out-of-pocket health expenditure >10%
or >25% of monthly total household expenditure or
income.26 We conducted additional analyses applying
these World Health Organization deﬁnitions. Distress
ﬁnancing, another common measure of health
ﬁnancing, was deﬁned as borrowing from family/
friends, selling possessions, or taking out loans to fund
dialysis care.24,25,27
Statistical Analyses
We followed STROBE (strengthening the reporting of
observational studies in epidemiology) guidelines for
observational studies to present descriptive data.28
Data were missing in fewer than 2% of patients, with
the exception of monthly household income (16%
missing). We used 4 categories for medical subsidy:
none, private insurance (self-paid or employer-
sponsored), charity, or government. In cases in which
patients had more than 1 source of subsidy (n ¼ 19),
government aid superseded other forms. We calculated
the proportion of patients with catastrophic health
expenditure and distress ﬁnancing, stratiﬁed by age,
sex, dialysis vintage, employment status, facility type,
monthly household income, and subsidy type. Because
catastrophic health expenditure and distress ﬁnancing
were common in our cohort, we estimated the adjusted
risk of these 2 outcomes using modiﬁed Poisson
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regression,29 with our exposure of interest being sub-
sidy type. In addition to the variables considered in
our stratiﬁed analysis, we included household size in
our model. Continuous measures were compared using
2-sample t-tests or Kruskal-Wallis tests as appropriate,
and categorical measures were compared using c2 tests.
We considered 2-tailed P values <0.05 as statistically
signiﬁcant. Analyses were performed using the Statis-
tical Analysis System (SAS) software, version 9.4 (SAS
Institute, Cary, NC).
Ethics Approval
Ethics approval was obtained for the study via the
Centre for Chronic Disease Control in New Delhi, India,
Stanford University School of Medicine in Palo Alto,
California, and the hospitals afﬁliated with the dialysis
units in Kerala, India.
RESULTS
A total of 835 patients on maintenance hemodialysis at
facilities in North (10 sites, n ¼ 540) and South (5 sites,
n ¼ 295) Kerala consented to participate in the study.
Table 1 describes patient demographics, cause of ESRD,
and dialysis prescription details, by subsidy type.
Men comprised most of our study population (n ¼
601, 72%), and most of our cohort attended private
facilities for hemodialysis (n ¼ 735, 88%), commensu-
rate with the overall distribution of public versus
private facilities in the state. The mean age of partici-
pants was 55  13 years, and median dialysis vintage
was 25 months (25th, 75th percentile range 12 to 48).
Patients in the no-subsidy or private insurance groups
were more likely to have a university education, be
employed, and have a higher income than those who
received charity or government subsidies; 139 (58%)
patients receiving government subsidy reported a
monthly household income of Indian rupees
(INR) #10,000 ($561 in 2017 international dollars
[INT$]30). A total of 175 (21%) patients underwent
twice-weekly hemodialysis; this prescription was most
common among persons who received government
support. Common causes of ESRD were diabetes and
hypertension, and were similar across subsidy groups.
There was widespread use of erythropoietin stimu-
lating agents (n ¼ 789, 95% of patients overall). Pa-
tients had experienced a median of 3 (25th, 75th
percentile range 1 to 7) hospitalizations since their
dialysis initiation.
Costs of Therapy
Figure 1 demonstrates the relative scale and breakdown
of direct versus indirect costs, overall and by subsidy
type. In the overall cohort, indirect expenses
comprised almost three-quarters of monthly spending,
with the largest contributor being lost wages. Most
direct costs were attributed to medications in the
government subsidy group, whereas patients in the no-
subsidy, private insurance, and charity groups had
substantial session-related direct costs.
Role of Subsidy in Catastrophic Health Expen-
ditures and Distress Financing
Figure 2 shows the amount of ﬁnancial assistance
received through private insurance, charity, or gov-
ernment aid. Median subsidy amounts were INR 20,930
(INT$1175) (25th, 75th percentile range 10,000
[INT$561] to 20,930 [INT$1175]), INR 5000 (INT$281)
(25th, 75th percentile range 3000 [INT$168] to 6000
[INT$337]), and INR 6400 (INT$359) (25th, 75th
percentile range 4500 [INT$253] to 7000 [INT$393]) for
private, charity and government subsidies, respec-
tively. Patients with private insurance received sub-
stantially more assistance than those in the charity or
government subsidy groups (P < 0.001).
A total of 759 (91%) patients experienced cata-
strophic health expenditure, with those receiving
charity subsidy most affected (Figure 3). Patients spent
a median of 80% (25th, 75th percentile range 60% to
90%) of their households’ nonsubsistence, or dispos-
able, income on dialysis-related care. Proportions for
catastrophic health expenditure were higher among
patients in the charity and government groups and
lower in the private insurance group, relative to the no-
subsidy group (Figure 3); the adjusted risk of cata-
strophic health expenditure did not differ by subsidy
type (relative risk 0.91 [95% conﬁdence interval 0.83–
1.01], 1.03 [95% conﬁdence interval 0.98–1.07], and
0.96 [95% conﬁdence interval 0.89–1.03] for private,
charity, and government subsidy groups, respec-
tively). When using alternate deﬁnitions of cata-
strophic health expenditure (dialysis-related expenses
>10% or >25% of total expenses26), the proportion of
patients experiencing ﬁnancial hardship was 97% and
92% for the 10% and 25% cutoffs, respectively.
A total of 644 (77%) patients engaged in distress
ﬁnancing, with a higher prevalence observed in the
charity and government groups versus the private in-
surance group. Table 2 shows that younger patients,
patients dialyzing in public facilities, and those with
lower household income were more likely to report
engaging in distress ﬁnancing. After adjustment for
socioeconomic and demographic factors, those in the
charity and government groups remained at higher risk
of distress ﬁnancing versus the no-subsidy group
(relative risk 1.23 [95% conﬁdence interval 1.11–1.36]
C Bradshaw et al.: Paying for Hemodialysis in Kerala, India CLINICAL RESEARCH
Kidney International Reports (2019) -, -–- 3
Table 1. Characteristics of patients on maintenance hemodialysis, by subsidy typea
Characteristic None n [ 356 Private n [ 82 Charity n [ 159 Government n [ 238
All
N [ 835
Demographics
Age, mean (SD)
Sex 58 (13) 59 (9) 52 (13) 53 (12) 55 (13)
Women 108 (30) 19 (23) 41 (26) 66 (28) 234 (28)
Men 248 (70) 63 (77) 118 (74) 172 (72) 601 (72)
Household size 4 (4, 6) 4 (4, 5) 5 (4, 6) 4 (4, 6) 4 (4, 6)
Education
None/below 5th grade 60 (17) 10 (12) 29 (18) 50 (21) 149 (18)
Completed 5th grade 86 (24) 27 (33) 59 (37) 71 (30) 243 (29)
Completed 12th grade 134 (38) 16 (20) 49 (31) 80 (34) 279 (33)
University or above 76 (21) 29 (35) 22 (14) 37 (16) 164 (20)
Occupation
Employed 58 (16) 22 (27) 21 (13) 30 (13) 131 (16)
Unemployed or retired 207 (58) 49 (60) 102 (64) 162 (68) 520 (62)
Student or homemaker 91 (26) 11 (13) 36 (23) 46 (19) 184 (22)
Household income/monthb
INR #10,000 59 (17) 14 (17) 36 (23) 139 (58) 248 (30)
10,001 to 40,000 169 (48) 52 (63) 91 (57) 72 (30) 384 (46)
$40,001 45 (13) 9 (11) 10 (6) 5 (2) 69 (8)
Missing 83 (23) 7 (8) 22 (14) 22 (9) 134 (16)
Dialysis details
Facility type
Private 350 (98) 81 (99) 159 (100) 145 (61) 735 (88)
Public 6 (2) 1 (1) – 93 (39) 100 (12)
Months on dialysis 24 (12, 47) 30 (16, 48) 33 (18, 60) 23 (12, 47) 25 (12, 48)
Sessions per week
Fewer than 3 71 (20) 12 (15) 4 (3) 107 (45) 194 (23)
Three or more 285 (80) 70 (85) 155 (98) 131 (55) 641 (77)
Session length (h)
Less than 3 3 (1) — 1 (1) 1 (0) 5 (1)
Three or more 353 (99) 82 (100) 158 (99) 237 (100) 830 (99)
Access
Fistula 307 (86) 71 (87) 156 (98) 213 (90) 747 (90)
Catheter 30 (8) 9 (11) 3 (2) 18 (8) 60 (7)
Graft 19 (5) 2 (2) — 7 (3) 28 (3)
Nature of dialysis start c
Planned 118 (33) 28 (34) 81 (51) 82 (35) 309 (37)
Emergent 222 (62) 51 (62) 75 (47) 151 (63) 499 (60)
Cause of ESRDd
Hypertension 191 (54) 42 (51) 118 (74) 120 (50) 471 (56)
Diabetes 177 (50) 44 (54) 64 (40) 91 (38) 376 (45)
Glomerulonephritis 5 (1) 4 (5) 2 (1) 6 (3) 17 (2)
Other/unknown 27 (8) 8 (10) 8 (5) 38 (16) 81 (10)
Medications
ESA 329 (92) 80 (98) 156 (98) 224 (94) 789 (95)
Phosphorus binders 265 (74) 64 (78) 143 (90) 159 (67) 631 (76)
Vitamin D 192 (54) 41 (50) 107 (67) 97 (41) 437 (52)
Heparin 290 (82) 75 (92) 153 (96) 224 (94) 742 (89)
Medical history
Comorbidities
Hypertension 280 (79) 63 (77) 143 (90) 177 (74) 663 (79)
Diabetes 222 (62) 50 (61) 82 (52) 119 (50) 473 (57)
Cardiovascular diseasee 85 (23) 19 (22) 15 (10) 71 (30) 190 (23)
Hospitalizations since dialysis start 3 (1, 8) 4 (1, 9) 4 (1, 10) 2 (1, 4) 3 (1,7)
ESRD, end-stage renal disease; ESA, erythropoietin stimulating agents; INR, Indian rupees.
aNumbers expressed as n (%) or median (25th, 75th percentile) unless otherwise indicated.
b2017 international dollar values, using purchasing power parity (PPP) conversion 17.81830: #$561, $562 to $2245, $$2245.
cParticipants who reported “I don’t know” are not presented.
dCategories are not mutually exclusive.
eIncludes self-reported history of myocardial infarction, congestive heart failure, and stroke.
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for the charity group and relative risk 1.22 [1.10–1.36]
for the government group).
DISCUSSION
Nine of 10 households in Kerala with a family member
on maintenance hemodialysis spend more than 40% of
their nonfood expenditure to support their therapy;
one-half of them spend more than 80% of this sum.
Despite availability of some form of subsidy in
approximately 60% of patients surveyed, hemodialysis
becomes the overriding ﬁnancial concern of house-
holds. Presence and type of subsidy were not asso-
ciated with lower rates of catastrophic health
expenditure, and patients receiving charity or gov-
ernment subsidies were more likely to engage in
distress ﬁnancing. The high prevalence of ﬁnancial
hardship among patients on maintenance hemodial-
ysis with or without subsidy highlights the need for
a more comprehensive approach to address ESRD in
resource-limited settings.
Our multicenter study is one of the largest to assess
the ﬁnancial hardship of maintenance hemodialysis in a
resource-constrained setting. Similar to South Africa,
Mexico, Brazil, Philippines, and China, India is experi-
encing rapid growth in its hemodialysis population.
Recent data indicate a 4-fold increase in dialysis utili-
zation in less than 5 years.31 Even as increasing infra-
structure for therapy remains an important concern,32,33
physicians, policymakers, and community advocates are
beginning to recognize the ﬁnancial repercussions of
starting patients on a costly life-long therapy, the
burden of which is often compounded by loss of
employment for 1 or more household members.34
The economic burden of hemodialysis for house-
holds is staggering. For context, using a deﬁnition
comparable to ours, approximately 4% of households
in Asian countries experienced catastrophic health
expenditure in 2010.21 A diagnosis of cancer or hos-
pitalizations for cardiovascular events in India causes
approximately one-half of affected households to
experience catastrophic health expenditure,25,35 but in
our study, hemodialysis led to near universal ﬁnancial
distress. A single-center study of patients undergoing
hemodialysis at a public facility in North India showed
that catastrophic health expenditure was present in
40% to 50% and distress ﬁnancing in approximately
60%36; the lower prevalence of catastrophic health
expenditure observed in the North Indian study could
be due to different patterns of patient reporting, more
external ﬁnancial support, and nature of facility (i.e.,
public) surveyed. Further, the authors did not include
lost wages in their cost assessment, which may have led
to an underestimation of the prevalence of catastrophic
health expenditure in their cohort. The sole study on
costs of hemodialysis from Kerala did not quantify
ﬁnancial hardship; however, the authors found that
direct costs of dialysis therapy outweighed indirect
costs, a ﬁnding that differs from our own, perhaps due
to how these categories were deﬁned (transportation
and opportunity costs from family involvement were
classiﬁed as “direct” costs) or differing patterns of
dialysis session coverage.37 We found that indirect
costs of travel or loss of employment accounted for
more than one-half of monthly dialysis-related ex-
penses; despite a mean age of 55 years, fewer than 30%
of these patients reported actively working. Their wage
losses are rarely recouped through unemployment or
medical disability beneﬁts, even in Kerala, where the
state government has been lauded for its social pro-
grams.38–40
Perhaps somewhat surprisingly, households of pa-
tients on hemodialysis without subsidy and/or with
private insurance still experienced signiﬁcant ﬁnancial
hardship as a result of hemodialysis, despite their
relative afﬂuence. Although the presence of savings or
other income reserves likely precluded engagement in
distress ﬁnancing in these groups, approximately 7 in
10 patients with private insurance reported experi-
encing catastrophic health expenditure. One reason for
this ﬁnding could be that patients in these groups
almost exclusively attended higher-cost private facil-
ities, where thrice-weekly dialysis is the standard and
the cost of the dialysis procedure was substantial. Pa-
tients receiving charity-based subsidies were also more
likely to attend dialysis thrice-weekly at private facil-
ities as compared with patients in the government
subsidy group, who received a comparable amount of
assistance and were otherwise similar demographically.
Wider reporting of quality metrics, including dialysis
water quality, stafﬁng ratios, rates of access-related
Figure 1. Breakdown of monthly direct and indirect dialysis-related
expenses, by subsidy type and overall. INR, Indian rupees.
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infections, hospital admissions, and mortality,41 are
crucial to ensuring that patients paying for higher-cost
facilities are in fact receiving care on par with national
standards. If government institutions are able to pro-
vide similar-quality care at lower costs, the overall
ﬁnancial burden of hemodialysis therapy could be
substantially reduced.
The high burden of ﬁnancial hardship in our study
highlights the inadequacy of medical subsidies for long-
term hemodialysis care. More than one-half of patients
receiving government subsidy reported monthly house-
hold incomesof INT$561 andbelow,whereas themonthly
cost of a twice-weekly hemodialysis session at a public
hospital is approximately INT$337; thus, were it not for
the government subsidy, hemodialysis would likely not
be an option. Several other countries, including the
Philippines and Malaysia, are adopting a “procedure
only” or “limited” subsidy approach as seen in our study.
InMalaysia, nongovernmental organizations that provide
hemodialysis at a discounted rate receive ﬁnancial bene-
ﬁts from the government.1 In the Philippines, PhilHealth,
the government-run insurance company, pays a ﬁxed
sum for 90 dialysis treatments per year.42 Although these
government subsidies may reduce the socioeconomic
disparities in the initiation of therapy, the long-term
sustainability of hemodialysis costs as experienced by
households has not been considered in detail.
Other approaches to mitigate the ﬁnancial hardship
associated with hemodialysis in low- andmiddle-income
countries are complex and varied, and it is important for
relevant authorities to be aware of and to build on what
has been done elsewhere while recognizing that there is
no one-size-ﬁts-all approach. First, chronic kidney dis-
ease screening programs for early detection and pre-
vention of disease progression are necessary.
Approximately 7%of the Indian population suffers from
diabetes,43 a major risk factor for chronic kidney disease,
and improved glycemic control can substantially slow
progression of kidney disease.44 In patients who none-
theless require renal replacement therapy, prioritization
of peritoneal dialysis and kidney transplantation may
not only be more cost-efﬁcient in the long-term,45,46 but
may also allow patients with ESRD to resume work. To
address organ shortage, it is necessary to build and
maintain deceased donor kidney transplant programs.47
Further, reduction of overhead costs can be achieved
through domestic manufacturing of health care goods.44
Inclusion of dialysis therapy in universal health care
packages is another option. Thailand has offered uni-
versal coverage for persons with ESRD with a “perito-
neal dialysis ﬁrst” approach2; however, it remains to be
seen if this policy change is economically sustainable,
particularly if applied to a more populous country like
India. Community-based insurance schemes that allow
patients to pool resources toward future medical ex-
penses also could be promoted.48 In many low- and
middle-income countries, rationing of health care re-
sources, including dialysis, may be inevitable; it is
therefore imperative for governments and health care
societies to develop transparent and evidence-based
Figure 2. Monthly ﬁnancial assistance, by subsidy type. Each dot represents a study participant, and the horizontal black bar represents the
median monthly amount in Indian rupees (INR) provided by the subsidy.
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guidelines for equitable distribution of these resources.3
In South Africa, patient selection criteria for public
ﬁnancing of dialysis have been instituted, and are
routinely reviewed to address socioeconomic in-
equalities in access.49 Finally, the health care commu-
nity also should use a more discerning approach to
counseling regarding renal replacement therapy. Inter-
national experts have called for physicians to engage in
transparent and thorough discussions with patients
regarding the medical and ﬁnancial burdens of dialysis,
and to offer the option of conservative, nondialytic care
where appropriate.3
Our study has several strengths. It is the ﬁrst multi-
center description of the ﬁnancial hardship experienced
by patients on hemodialysis in a resource-constrained
setting, with a representative ratio of private and pub-
lic facilities. We also speciﬁcally examine the association
of medical subsidies with household ﬁnancial hardship,
which can inform policy makers as they consider
further strategies for health care ﬁnancing. Our study
also has limitations. First, given that much of our data
are based on self-report, recall bias and misclassiﬁcation
of outcome are possible; however, these methods have
been used in other studies examining ﬁnancial hardship
in low- and middle-income countries, where precise
measurements of wealth or prosperity are difﬁcult to
obtain.21,50 We attempted to corroborate patient-
reported medical history and medications with facility
documentation where available, and we tried to mini-
mize confounding by adjusting for various socioeco-
nomic and demographic factors. Nonetheless, residual
confounding is likely present, and the observational
nature of our study calls for cautious interpretation of
any causal relationships. Second, the cost estimates are
reported as an “average” monthly expense, and do not
capture potential variations over time. Given the high
number of prevalent patients surveyed, it is possible
that these patients’ income, and therefore ability to pay
for hemodialysis, changed signiﬁcantly since dialysis
initiation. As there is no centralized statewide ESRD
registry, we cannot compare our cohort with the overall
Kerala hemodialysis population. However, on the basis
of a recently published nationwide estimate of the
numbers of kidney failure–related deaths in India from
the Million Death Study, our survey of 15 facilities
roughly reﬂects approximately 35% of the total hemo-
dialysis units in Kerala.20 Further, most (>65%) of our
patients are men, aged 45 to 55 years, and use private
facilities, similar to hemodialysis patients enrolled in a
statewide claims-based analysis from Andhra Pradesh.31
Due to the relative afﬂuence and high level of education
found in Kerala, we may underestimate the true ﬁnancial
burden of hemodialysis in the rest of India. Lastly, we
do not yet have data to assess the effects of medical
subsidy and/or ﬁnancial hardship on health outcomes in
this population.
In summary, we found that households with pa-
tients on maintenance hemodialysis in Kerala experi-
enced crippling levels of ﬁnancial hardship related to
Figure 3. Prevalence of catastrophic health expenditure and
distress ﬁnancing, by subsidy type. The private group had signiﬁ-
cantly lower catastrophic health expenditure (CHE) and distress
ﬁnancing (DF) versus the none, charity, or government groups in
unadjusted analyses (P < 0.001).
Table 2. Catastrophic health expenditure and distress ﬁnancing by
select patient demographics
Characteristic
Catastrophic health
expenditurea (%)
Distress
ﬁnancingb (%)
Age (yr)
< 44 93 84c
45 to 64 94 79
$ 65 91 69
Sex
Men 93 78
Women 93 75
Occupation
Employed 95 73
Unemployed/retired 92 78
Student/homemaker 94 77
Years on dialysis
<1 94 74
$1 to <3 92 78
$3 93 78
Sessions/week
Fewer than 3 90 78
Three or more 94 78
Facility type
Public 92 94c
Private 93 75
Monthly household income, INR
#10,000 91 86c
10,001–40,000 90 75
$40,001 96 55
Missing 93 79
aCatastrophic health expenditure defined as dialysis-related expenditure $40% of
nonsubsistence expenditure.24
bDistress financing defined as borrowing from family/friends, selling property, or taking
out bank loan.25,27
cChi-square P < 0.005.
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treatment, despite availability of a variety of medical
subsidies. Given the signiﬁcant psychosocial and
ﬁnancial ramiﬁcations of an ESRD diagnosis in
resource-constrained settings, governments and health
care providers must work together to develop sus-
tainable strategies to provide equitable health care
ﬁnancing for this vulnerable population.
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